Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 3, 2013, Pages 269-279

  Tang, An ^a,b   Cruite, Irene ^a,c   Sirlin, Claude B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

cirrhosis; computed tomography; diagnosis; dysplastic nodule; hepatocellular carcinoma; LI RADS; magnetic resonance imaging

Indexed keywords

CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; EVIDENCE BASED MEDICINE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL SOCIETY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; RADIOLOGIST; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; DISEASE MANAGEMENT; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84874630856     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.13.3     Document Type: Review

References (31)

1. Taouli B, Krinsky GA. Diagnostic imaging of hepatocellular carcinoma in patients with cirrhosis before liver transplantation. Liver Transpl. 12(11 Suppl. 2), S1-S7 (2006).
2. Krinsky G. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers. Intervirology 47(3-5), 191-198 (2004).
3. Burrel M, Llovet JM, Ayuso C et al.; Barcelona Clínic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38(4), 1034-1042 (2003).
4. Hanna RF, Kased N, Kwan SW et al. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR. Am. J. Roentgenol. 190(1), 47-57 (2008).
5. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3), 1020-1022 (2011).
6. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908-943 (2012).
7. Song P, Tobe RG, Inagaki Y et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 32(7), 1053-1063 (2012).
8. Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am. J. Surg. 195(6), 829-836 (2008).
9. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42(5), 1208-1236 (2005).
10. Bruix J, Sherman M, Llovet JM et al.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35(3), 421-430 (2001).
11. Ito K, Mitchell DG, Siegelman ES. Cirrhosis: MR imaging features. Magn. Reson. Imaging Clin. N. Am. 10(1), 75-92, VI (2002).
12. Brancatelli G, Federle MP, Ambrosini R et al. Cirrhosis: CT and MR imaging evaluation. Eur. J. Radiol. 61(1), 57-69 (2007).
13. Kudo M, Izumi N, Kokudo N et al.; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 29(3), 339-364 (2011).
14. Memon K, Kulik L, Lewandowski RJ et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141(2), 526-535, 535.e1 (2011).
15. Freeman RB, Mithoefer A, Ruthazer R et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl. 12(10), 1504-1511 (2006).
16. Jelic S, Sotiropoulos GC; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v59-v64 (2010).
17. Omata M, Lesmana LA, Tateishi R et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 4(2), 439-474 (2010).
18. Pomfret EA, Washburn K, Wald C et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl. 16(3), 262-278 (2010).
19. Brancatelli G, Federle MP, Blachar A, Grazioli L. Hemangioma in the cirrhotic liver: diagnosis and natural history. Radiology 219(1), 69-74 (2001).
20. Jeong YY, Yim NY, Kang HK. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules. AJR. Am. J. Roentgenol. 185(4), 1024-1032 (2005).
21. Baron RL, Peterson MS. From the RSNA refresher courses: screening the cirrhotic liver for hepatocellular carcinoma with CT and MR imaging: opportunities and pitfalls. Radiographics 21, S117-S132 (2001).
22. Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 254(1), 154-162 (2010).
23. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255(2), 459-466 (2010).
24. Motosugi U, Ichikawa T, Sou H et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256(1), 151-158 (2010).
25. Lee S, Kim SH, Park CK, Kim YS, Lee WJ, Lim HK. Comparison between areas with Gd-EOB-DTPA uptake and without in hepatocellular carcinomas on Gd-EOBDTPA-enhanced hepatobiliary-phase MR imaging: pathological correlation. J. Magn. Reson. Imaging 32(3), 719-725 (2010).
26. Schneider G, Reimer P, Mamann A, Kirchin MA, Morana G, Grazioli L. Contrast agents in abdominal imaging: current and future directions. Top. Magn. Reson. Imaging 16(1), 107-124 (2005).
27. Sakata J, Shirai Y, Wakai T, Kaneko K, Nagahashi M, Hatakeyama K. Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur. J. Surg. Oncol. 34(8), 900-905 (2008).
28. Takizawa D, Kakizaki S, Sohara N et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig. Dis. Sci. 52(11), 3290-3295 (2007).
29. Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J. Magn. Reson. Imaging 18(2), 189-195 (2003).
30. Langlotz CP. RadLex: a new method for indexing online educational materials. Radiographics 26(6), 1595-1597 (2006).
31. Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1), 97-104 (2008).